Iyer, G., Ebi, H., Cook, N., Gao, X., Kitano, S., Matsubara, N., Reimers, M. A., Siefker-Radtke, A. O., Kim, M., Galsky, M. D., Robbrecht, D. G., Guo, J., Eigl, B. J., Schaverien, C., Butts, B., Yuen, E., Szymczak, S., Zhao, X., Widau, R. C., Drakaki, A. (2025). A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.662